Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin
about
The type XIII collagen ectodomain is a 150-nm rod and capable of binding to fibronectin, nidogen-2, perlecan, and heparinPerlecan protein core interacts with extracellular matrix protein 1 (ECM1), a glycoprotein involved in bone formation and angiogenesisThe anti-angiogenic His/Pro-rich fragment of histidine-rich glycoprotein binds to endothelial cell heparan sulfate in a Zn2+-dependent mannerExtended interaction network of procollagen C-proteinase enhancer-1 in the extracellular matrixThe first draft of the endostatin interaction networkInteraction of endostatin with integrins implicated in angiogenesisQSulf1 remodels the 6-O sulfation states of cell surface heparan sulfate proteoglycans to promote Wnt signalingThe response of VEGF-stimulated endothelial cells to angiostatic molecules is substrate-dependent.Hallmarks of glycosylation in cancerAn in vivo neovascularization assay for screening regulators of angiogenesis and assessing their effects on pre-existing vessels.Sequencing of 3-O sulfate containing heparin decasaccharides with a partial antithrombin III binding site.Sulfation, the up-and-coming post-translational modification: its role and mechanism in protein-protein interactionExtracellular matrix modulates angiogenesis in physiological and pathological conditions.Collagens and collagen-related diseases.Domain-specific modification of heparan sulfate by Qsulf1 modulates the binding of the bone morphogenetic protein antagonist Noggin.Discovery of novel sulfonated small molecules that inhibit vascular tube formationHeparan sulfate proteoglycans: heavy hitters in the angiogenesis arenaRole of heparan sulfate domain organization in endostatin inhibition of endothelial cell function.Cellular actions and signaling by endostatin.Delivery of endostatin in experimental cancer therapy.Increased angiogenic response in aortic explants of collagen XVIII/endostatin-null mice.Characterisation of the interaction of neuropilin-1 with heparin and a heparan sulfate mimetic library of heparin-derived sugars.Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapyEndostatin's emerging roles in angiogenesis, lymphangiogenesis, disease, and clinical applications.Endorepellin causes endothelial cell disassembly of actin cytoskeleton and focal adhesions through alpha2beta1 integrin.Structural basis for the functions of endogenous angiogenesis inhibitors.Endostatin and endorepellin: A common route of action for similar angiostatic cancer avengersImproved biological activity of a mutant endostatin containing a single amino-acid substitutionIdentification of Peptides Derived from the C-terminal Domain of Fibulin-7 Active for Endothelial Cell Adhesion and Tube Formation Disruption.Establishment of a survival and toxic cellular model for Parkinson's disease from chicken mesencephalon.Molecular interplay between endostatin, integrins, and heparan sulfate.Recombinant production of proteoglycans and their bioactive domains.Heparan sulfate in angiogenesis: a target for therapy.Binding of endostatin to endothelial heparan sulphate shows a differential requirement for specific sulphates.The Challenges of Recombinant Endostatin in Clinical Application: Focus on the Different Expression Systems and Molecular Bioengineering.The morphogenic properties of oligomeric endostatin are dependent on cell surface heparan sulfate.Radiation-enhanced endostatin gene expression and effects of combination treatment.Differential endostatin binding to bladder, prostate and kidney tumour vessels.An endostatin-derived peptide interacts with integrins and regulates actin cytoskeleton and migration of endothelial cells.Transglutaminase-2: a new endostatin partner in the extracellular matrix of endothelial cells.
P2860
Q24294514-3ED1B8AB-535F-4B61-93F8-77ECE725722EQ24295251-4966275D-87BE-4CEC-89E5-6713D0362E3EQ24302060-5DB472CB-43BB-4BD1-A6CC-943BED3BF60CQ24338239-87A4C742-5D51-4A5A-BFE3-3CCD46A8646EQ24338820-38F53F26-9590-496C-88C4-CF3038F10D0CQ24545535-011F09CA-76E6-44B0-AB34-FD3730587488Q24675509-63350750-173C-4D86-B430-D2A014EFCC0EQ24811681-45C0EFB5-B6F8-4A84-95F9-B1B99CA4C097Q26752363-BAB10092-6029-4CD9-9D4B-81C94065EF7AQ30528295-3FA944CF-9E0F-46BB-A2C5-D4F80394ECA3Q33181061-F24628EA-7510-4925-B30E-5F54C71EE2CEQ33270497-677ADCC4-C0D8-4067-96DE-E5C42A56FD7EQ33737210-3DC1B930-3C38-4E24-A6C2-7B52DE8FCE97Q34224267-23B15FCB-B9D1-429A-B57A-AAB87DCB93BBQ34279840-CAE5476B-A60A-494A-8263-8E4964081985Q34280914-8542F0B3-7CEE-42A3-AD64-D8E11AED34ECQ34328750-8D6B1A1E-29A1-455A-B190-76D10A3E1A85Q34361094-EDB24253-495E-4068-A27B-0390BFD83B68Q35008096-5108F9F9-BC2C-4FF7-B9BC-8FFEE1C886F3Q35092178-80CE44A0-3AFF-4BF0-8EB5-3D7FEA9C3117Q35103055-AC5B51C0-1E91-4750-B0DA-E21AFFCC5C68Q35206904-9F548CCB-CABF-4395-A022-EDF09AEAB784Q35800448-0B571143-77EC-4615-ADFD-943120376FE8Q36220259-E2818E76-82B4-43A4-A5F0-F4ECDAFEE0AAQ36322054-58FA6495-373C-4019-8496-9B2F5A4C3CEEQ36547755-6976DC98-2A38-44E8-B098-00A6C1698682Q36578668-5DA93BC6-B9DD-406F-82DF-D96891563F8FQ36694928-BECBB78C-3CF7-42B9-B3C0-C6A1018C43E3Q36827495-195239D6-2B10-4DE7-99BF-BA900B67003CQ36952026-40E09045-AE3E-4C27-B279-A7B1FE6B288CQ37372196-8E5D7250-E1B5-465A-BDB9-4CD058D0C1E3Q38082553-42A75297-8171-4A42-AEFB-CF90896C5779Q38154506-BD1A90ED-A68A-4FA7-AEF3-7599C3A7F2E4Q38353503-3C49520C-269D-42FC-BD7A-DE10CE285E20Q39308829-87FB7129-6EDC-4A6D-92B4-88A9B7AA99C0Q40315779-FB7CFF10-6482-4ADB-926B-BFD427BA7F47Q40445708-2EB84AF9-B56C-4D03-8A90-AF3A89121443Q40456169-BF32112F-B089-4026-82F3-A2B3F90DF0C3Q40588037-009797E6-00F3-408E-B689-16BC96D0F3C6Q40760483-B2756EFB-E506-479A-A904-57A8E05C1ECA
P2860
Structural basis and potential role of heparin/heparan sulfate binding to the angiogenesis inhibitor endostatin
description
1999 nî lūn-bûn
@nan
1999 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Structural basis and potential ...... iogenesis inhibitor endostatin
@ast
Structural basis and potential ...... iogenesis inhibitor endostatin
@en
Structural basis and potential ...... iogenesis inhibitor endostatin
@en-gb
Structural basis and potential ...... iogenesis inhibitor endostatin
@nl
type
label
Structural basis and potential ...... iogenesis inhibitor endostatin
@ast
Structural basis and potential ...... iogenesis inhibitor endostatin
@en
Structural basis and potential ...... iogenesis inhibitor endostatin
@en-gb
Structural basis and potential ...... iogenesis inhibitor endostatin
@nl
prefLabel
Structural basis and potential ...... iogenesis inhibitor endostatin
@ast
Structural basis and potential ...... iogenesis inhibitor endostatin
@en
Structural basis and potential ...... iogenesis inhibitor endostatin
@en-gb
Structural basis and potential ...... iogenesis inhibitor endostatin
@nl
P2093
P356
P1433
P1476
Structural basis and potential ...... iogenesis inhibitor endostatin
@en
P2093
E Hohenester
L Claesson-Welsh
M Salmivirta
P304
P356
10.1093/EMBOJ/18.22.6240
P407
P577
1999-11-15T00:00:00Z